Vendor comparison · 2026
HGH Fragment 176-191 vendors: 4 compared on COAs and price
MetabolicAlso known as HGH Frag 176-191, Growth hormone fragment 176-191, Frag 176-191
Evidence tier
Limited published literature
4 publications over 48 years · trials not yet curated
- Vendors carrying it
- 4
- 4 with a listed price
- Vendors with checkable COAs
- 0
- 0 publish any certificate
- Lots tested
- 0
- 0 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- —
- Laboratories named
- 0
- Median label gap
- —
- Median purity
- —
- Lowest price per mg
- $8.00
- peer median $8.80
- Publications located
- 4
- researched since 1978
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
No indexed vendor publishes a HGH Fragment 176-191 certificate naming a laboratory this index could check, so no vendor can be called well-tested for it yet. The lowest listed price is $8.00 per mg at GenX Peptides, against a peer median of $8.80. 4 vendors carrying HGH Fragment 176-191 are compared below. 0 publish at least one certificate naming a checkable laboratory, no lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying HGH Fragment 176-191
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Modern AminosISO/IEC 17025COAs need an account | 80.997% | $8.80 (100%) | 0 | — | — | — | — | no reportVisit site |
| 2 | Simple Peptide | 76.492% | $10.00 (114%) | 0 | — | — | — | — | no reportVisit site |
| 3 | GenX Peptides | 67.669% | $8.00 (91%) | 0 | — | — | — | — | no reportVisit site |
| 4 | Biotech Peptides | 62.160% | $8.80 (100%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of HGH Fragment 176-191 is on file. No certificate for it has been indexed at all. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
Laboratories used
No certificate for HGH Fragment 176-191 names a laboratory this index could identify.
Every certificate record
No certificate record for HGH Fragment 176-191 is indexed. Either no vendor publishes one, or those published could not be read without an account.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1978 — 48 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
4 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
4 of 4 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is HGH Fragment 176-191?
A synthetic fragment corresponding to residues 176-191 of human growth hormone, studied in animal models for effects on lipid metabolism. The stabilised analogue AOD-9604 is tracked separately in this index.
Studied in published research for fat metabolism and weight loss.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review — The Journal of sports medicine and physical fitness (2026)
Peer-reviewed article indexed in PubMed, published in The Journal of sports medicine and physical fitness (2026).
- Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells — Drug design, development and therapy (2022)
Peer-reviewed article indexed in PubMed, published in Drug design, development and therapy (2022).
- Hyperglycemic action of synthetic C-terminal fragments of human growth hormone — The American journal of physiology (1978)
Peer-reviewed article indexed in PubMed, published in The American journal of physiology (1978).
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Frontiers in endocrinology (2026)
Peer-reviewed article indexed in PubMed, published in Frontiers in endocrinology (2026).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.